Abstract
The application of Au(I) ions in pharmaceuticals, including in nuclear medicine, is limited by their instability towards reduction in vivo. The gold radionuclide 198Au with a half-life of 2.7 days emits gamma radiation ideal for diagnostic purposes and also generates β- particles suitable for effective cancer radiotherapy, making it a perfect nuclide for ‘theranostics’. Here, we explore N-heterocyclic carbene (NHC) organometallic chemistry to stabilize 198Au(I) in radiopharmaceuticals. Thus, different Au(I) NHC compounds featuring different scaffolds have been selected for 198Au radiolabeling. Two new benzimidazol-2-ylidene Au(I) complexes bearing peptide ligands enabling blood brain barrier translocation in vitro have also been synthesized and their radiolabeling attempted. The obtained proof-of-concept results showed that NHCs are suitable ligands to achieve isotope exchange in Au(I) complexes, with imidazole derivatives being particularly stable, also in the presence of AuCl(THT) and human serum albumin. Overall, our work reveals the still untapped potential of organometallic chemistry in radiopharmaceutical design.

This publication has 47 references indexed in Scilit: